Skip to main content

RA Capital Healthcare Fund LP's Form 4 filing

iTeos Therapeutics, Inc. (ITOS) · filed May 14, 2024

Accession no.
0001415889-24-013171
Filed
May 14, 2024, 9:06 PM ET
Trade date
May 10-12, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction and 2 derivative transactions. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
RA Capital Healthcare Fund LPCIK 0001315082Other: Former 10% Owner
Ra Capital Management, L.P.CIK 0001346824Other: Former 10% Owner
Kolchinsky PeterCIK 0001384859Other: Former 10% Owner
Shah Rajeev M.CIK 0001619841Other: Former 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 12, 2024Common StockJOtherDisposed−900,000–F1–2,545,510Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 10, 2024Common StockPPurchaseAcquired+5,714,285$17.50+$99,994,273.225,714,285Indirect
May 12, 2024Common StockJOtherAcquired+900,000–F1–6,614,285Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On May 12, 2024, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an exchange agreement with the Issuer, pursuant to which the Fund agreed to exchange 900,000 shares of the Issuer's Common Stock for a pre-funded warrant to purchase up to 900,000 shares of Common Stock.

Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)